Filtered By:
Source: Nanomedicine: Nanotechnology, Biology and Medicine
Cancer: Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 27 results found since Jan 2013.
Simultaneous inhibition of CD73 and IL-6 molecules by siRNA-loaded nanoparticles prevents the growth and spread of Cancer
Publication date: Available online 24 March 2021Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Sima Emadi Allahyari, Farnaz Hajizadeh, Angelina Olegovna Zekiy, Niloofar Mansouri, Parisa Sahami Gilan, Seyedeh Mahboubeh Mousavi, Ali Masjedi, Hadi Hassannia, Majid Ahmadi, Hamed Mohammadi, Mehdi Yousefi, Sepideh Izadi, Naime Majidi Zolbanin, Reza Jafari, Farhad Jadidi-Niaragh
Source: Nanomedicine: Nanotechnology, Biology and Medicine - March 25, 2021 Category: Nanotechnology Source Type: research
Growth inhibitory and anti-metastatic activity of epithelial cell adhesion molecule targeted three-way junctional Delta-5-Desaturase siRNA nanoparticle for breast cancer therapy
Publication date: Available online 12 September 2020Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Harshit Shah, Lizhi Pang, Hongzhi Wang, Dan Shu, Steven Y. Qian, Venkatachalem Sathish
Source: Nanomedicine: Nanotechnology, Biology and Medicine - September 14, 2020 Category: Nanotechnology Source Type: research
Folate receptor-targeted RNAi nanoparticles for silencing STAT3 in tumor-associated macrophages and tumor cells
Publication date: Available online 18 February 2020Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Jing Chen, Yushun Dou, Yue Tang, Xinru ZhangAbstractWe developed a STAT3 silencing siRNA to both tumor cells and M2 macrophages. The dual-targeting system prepared by electronic self-assembly was composed of folic acid-conjugated carboxymethyl chitosan for targeting and cationic chitosan derivatives for siRNA package. The effects of siRNA delivery was investigated in M2 macropahges and Lewis lung cancer cells(LLC). Due to the enhanced delivery efficiency, the dual-targeting delivery system exhibited a hig...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - February 19, 2020 Category: Nanotechnology Source Type: research
Silencing AXL by covalent siRNA-gelatin-antibody nanoconjugate inactivates mTOR/EMT pathway and stimulates p53 for TKI sensitization in NSCLC
Publication date: Available online 12 May 2019Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Dhananjay Suresh, Ajit Zambre, Soumavo Mukherjee, Shreya Ghoshdastidar, Yuexu Jiang, Trupti Joshi, Anandhi Upendran, Raghuraman KannanAbstractNon-small cell lung cancer (NSCLC) is the leading cause of cancer mortality with the 5-year survival rate remains a dismal 16% for the past 40 years. Drug resistance is a major obstacle to achieving long-term patient survival. Identifying and validating molecular biomarkers responsible for resistance and thereby adopting multi-directional therapy is necessary to imp...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - May 12, 2019 Category: Nanotechnology Source Type: research
Cationic lipoplexes for treatment of cancer stem cell-derived murine lung tumors
This study outlines the fabrication of a lipoplex of SOX2 small interfering RNA (CL-siSOX2) for targeted treatment of SOX2-enriched, CSC-derived orthotopic and xenograft lung tumors in CB-17 SCID mice. CL-siSOX2 induced tumor contraction in cisplatin-naïve and cisplatin-treated groups by 85% and 94% respectively. Reduction in tumor weight and volume following treatment with CL-siSOX2 was associated with reduced protein expression of SOX2 and markers of tumor initiation, inflammation, invasion and metastasis in mice tumor xenografts. In addition, histological staining of lung tumor sections showed reduction in SOX2 express...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - March 20, 2019 Category: Nanotechnology Source Type: research
Cationic lipoplexes for treatment of cancer stem cell-derived murine lung tumors.
This study outlines the fabrication of a lipoplex of SOX2 small interfering RNA (CL-siSOX2) for targeted treatment of SOX2-enriched, CSC-derived orthotopic and xenograft lung tumors in CB-17 SCID mice. CL-siSOX2 induced tumor contraction in Cisplatin-naïve and Cisplatin-treated groups by 85% and 94% respectively. Reduction in tumor weight and volume following treatment with CL-siSOX2 was associated with reduced protein expression of SOX2 and markers of tumor initiation, inflammation, invasion and metastasis in mice tumor xenografts. And histological staining of lung tumor sections showed reduction in SOX2 expression was a...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - March 1, 2019 Category: Nanotechnology Source Type: research
Smart nanoparticles assembled by endogenous molecules for siRNA delivery and Cancer therapy via CD44 and EGFR dual-targeting
Publication date: Available online 21 October 2018Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Yaoyao Liang, Jiahui Peng, Ning Li, Cynthia Yu-Wai-Man, Qian Wang, Yuhong Xu, Hongxia Wang, Aristides D Tagalakis, Zixiu DuAbstractWe developed an anticancer siRNA delivery system (named HLPR) through modular assembly of endogenous molecules. The structure of HLPR was a tightly condensed siRNA-peptide inner core in turn surrounded by the disordered lipid layer and thin HA coating from which the EGFR-targeted amino acid sequences of IVNQPTYGYWHY partially protrude outside of cell surfaces. Both HA and IVNQP...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - October 21, 2018 Category: Nanotechnology Source Type: research
Enhancing the therapeutic effect via elimination of hepatocellular carcinoma stem cells using Bmi1 siRNA delivered by cationic cisplatin nanocapsules
Publication date: Available online 26 May 2018Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Tan Yang, Yuyuan Chen, Pengxuan Zhao, Huiying Xue, Jia You, Bin Li, Yong Liu, Chuanchuan He, Xiaojuan Zhang, Lingling Fan, Robert J. Lee, Lei Li, Xiang Ma, Chuanrui Xu, Guangya XiangResistance of hepatocellular carcinoma (HCC) to systemic chemotherapy is partially due to presence of drug-resistant cancer stem cells. Bmi1 protein is essential for survival and proliferation of HCC cancer stem cells (CSCs). Here, we report that Bmi1 siRNA (Bmi1siR) loaded in cationic nanocapsules of cisplatin (NPC) eliminated ste...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - July 10, 2018 Category: Nanotechnology Source Type: research
Mannose-conjugated layered double hydroxide nanocomposite for targeted siRNA delivery to enhance cancer therapy
Publication date: Available online 22 June 2017Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Li Li, Run Zhang, Wenyi Gu, Zhi Ping XuAbstractSheet-like layered double hydroxide nanoparticles (LDH NPs) have showed great potentials in biomedical applications such as nanocarriers for drug and gene delivery, biosensors and imaging agents. However, target delivery of drugs and genes using LDH NPs to the desired tumor sites is a major challenge in cancer therapy. The aim of this study is to develop a functional LDH-based nanocomposite for target delivery of siRNA to cancer cells. Mannose as a targeting moie...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - July 10, 2018 Category: Nanotechnology Source Type: research
Enhancing the therapeutic effect via elimination of hepatocellular carcinoma stem cells using Bmi1 siRNA delivered by cationic cisplatin nanocapsules
Publication date: Available online 26 May 2018Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Tan Yang, Yuyuan Chen, Pengxuan Zhao, Huiying Xue, Jia You, Bin Li, Yong Liu, Chuanchuan He, Xiaojuan Zhang, Lingling Fan, Robert J. Lee, Lei Li, Xiang Ma, Chuanrui Xu, Guangya XiangResistance of hepatocellular carcinoma (HCC) to systemic chemotherapy is partially due to presence of drug-resistant cancer stem cells. Bmi1 protein is essential for survival and proliferation of HCC cancer stem cells (CSCs). Here, we report that Bmi1 siRNA (Bmi1siR) loaded in cationic nanocapsules of cisplatin (NPC) eliminated ste...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - July 5, 2018 Category: Nanotechnology Source Type: research
Mannose-conjugated layered double hydroxide nanocomposite for targeted siRNA delivery to enhance cancer therapy
Publication date: Available online 22 June 2017Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Li Li, Run Zhang, Wenyi Gu, Zhi Ping XuAbstractSheet-like layered double hydroxide nanoparticles (LDH NPs) have showed great potentials in biomedical applications such as nanocarriers for drug and gene delivery, biosensors and imaging agents. However, target delivery of drugs and genes using LDH NPs to the desired tumor sites is a major challenge in cancer therapy. The aim of this study is to develop a functional LDH-based nanocomposite for target delivery of siRNA to cancer cells. Mannose as a targeting moie...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - July 5, 2018 Category: Nanotechnology Source Type: research
Enhancing the therapeutic effect via elimination of hepatocellular carcinoma stem cells using Bmi1 siRNA delivered by cationic cisplatin Nanocapsules
Publication date: Available online 26 May 2018 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Tan Yang, Yuyuan Chen, Pengxuan Zhao, Huiying Xue, Jia You, Bin Li, Yong Liu, Chuanchuan He, Xiaojuan Zhang, Lingling Fan, Robert J. Lee, Lei Li, Xiang Ma, Chuanrui Xu, Guangya Xiang Resistance of hepatocellular carcinoma (HCC) to systemic chemotherapy is partially due to presence of drug-resistant cancer stem cells. Bmi1 protein is essential for survival and proliferation of HCC cancer stem cells (CSCs). Here, we report that Bmi1 siRNA (Bmi1siR) loaded in cationic nanocapsules of cisplatin (NPC) eliminated ...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - May 27, 2018 Category: Nanotechnology Source Type: research
Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer
Publication date: Available online 14 April 2018 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Sophia A. Shahin, Ruining Wang, Shirleen I. Simargi, Altagracia Contreras, Liliana Parra, Louise Qu, Wei Wen, Thanh Dellinger, Juli Unternaehrer, Fuyuhiko Tamanoi, Jeffrey I. Zink, Carlotta A. Glackin TWIST protein is critical to development and is activated in many cancers. TWIST regulates epithelial-mesenchymal transition, and is linked to angiogenesis, metastasis, cancer stem cell phenotype, and drug resistance. The majority of epithelial ovarian cancer (EOC) patients with metastatic disease respond wel...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - April 15, 2018 Category: Nanotechnology Source Type: research
Intraperitoneal Nanotherapy for Metastatic Ovarian Cancer Based on siRNA-Mediated Suppression of DJ-1 Protein Combined with a Low Dose of Cisplatin
Publication date: Available online 7 April 2018 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Canan Schumann, Stephanie Chan, Jess A. Millar, Yuliya Bortnyak, Katherine Carey, Alex Fedchyk, Leon Wong, Tetiana Korzun, Abraham S. Moses, Anna Lorenz, Delany Shea, Olena Taratula, Oleh Khalimonchuk, Oleh Taratula Herein, we report an efficient combinatorial therapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin. DJ-1 protein modulates, either directly or indirectly, different oncogenic pathways that support and promote survival, gro...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - April 8, 2018 Category: Nanotechnology Source Type: research
Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment
Publication date: Available online 16 November 2017 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Narsireddy Amreddy, Anish Babu, Janani Panneerselvam, Akhil Srivastava, Ranganayaki Muralidharan, Allshine Chen, Yan D. Zhao, Anupama Munshi, Rajagopal Ramesh Co-administration of functionally distinct anti-cancer agents has emerged as an efficient strategy in lung cancer treatment. However, a specially designed drug delivery system is required to co-encapsulate functionally different agents, such as a combination of siRNA and chemotherapy, for targeted delivery. We developed a folic acid (FA) -conjugat...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - November 28, 2017 Category: Nanotechnology Source Type: research
